November 15, 2018
Precision BioSciences and MaxCyte Enter into Clinical and Commercial Agreement
Precision BioSciences gains rights to MaxCyte’s cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision’s ARCUS® genome-editing technology.
Precision BioSciences (Precision) and MaxCyte announced today they have entered into a non-exclusive, clinical and commercial license agreement which allows Precision to use MaxCyte’s Flow Electroporation® technologies to actively deliver Precision’s proprietary ARCUS genome-editing technology for use in next-generation gene edited allogeneic T-cell immunotherapies designed to treat a broad range of cancers.
David Thomson, Chief Development Officer of Precision, expressed great support for the agreement, noting, “Precision’s therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems. In considering these, we have found MaxCyte’s electroporation technology complements our approach to allogeneic T-cell manufacturing, which is focused on preserving cell quality throughout the process while maximizing overall yield.”
[Originally posted by Precision BioSciences — November 14, 2018]